<DOC>
	<DOCNO>NCT01081782</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy ONO-4641 patient relapsing-remitting multiple sclerosis 26-week treatment period .</brief_summary>
	<brief_title>A Study Safety Efficacy ONO-4641 Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Adult male female age 1855 year inclusive screening Patients definite diagnosis relapsingremitting Multiple Sclerosis Multiple Sclerosis course relapsingremitting multiple sclerosis History malignancy History clinically significant chronic disease immune system ( Multiple Sclerosis ) Inability undergo Gdenhanced MRI scan Diagnosis diabetes mellitus ( type I type II )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>ONO-4641</keyword>
</DOC>